What would be your prediction for those who are both unvaccinated against COVID-19 and never previously infected? Let's say those of working age(20 - 55) in fairly good health.
Should they be worried about Avian Flu and Monkeypox, since they have not experienced an infection by SARS-CoV-2?
Are they at risk for serious illness from these more infectious (and future more virulent) SARS-CoV-2 mutants?
It would be quite unbelievable that they didn’t get exposed to SC-2 given the high infectiousness of previously and currently circulating variants. Ideally, they should have their Abs tested (anti-S would be sufficient since they’re not vaccinated). They can also have their Abs tested against Flu. If all this is negative (which would point to poor activation of natural immunity), they can just take one shot of a live attenuated measles or mumps or rubella or varicella vaccine (or all together in one shot) to boost their innate immune response. (However, they should only do so if they got MMR(V)-vaccinated in the past. The better their innate immune status, the lower the likelihood they are going to catch severe disease from these viruses. But anyhow, for a person in good health, it is highly unlikely to develop severe disease from Monkeypox (as it is - for now(!) - not highly infectious) or from Avian Flu as they must at least have had contact with Flu viruses in the past and hence, have some ‘Flu-trained’ innate immunity.)
Unvaccinated can now largely forget about contracting severe C-19 disease as the next big mutation will most likely make the unvaccinated resistant to the virus. However, if they have not yet been infected at all by any of these highly infectious variants, they could still contract C-19 disease (before that new variant emerges) and become seriously ill (but not ‘severely ill’ as longas they are in good health with no comorbidities and predisposing factors). To avoid this, they should either prevent risky contacts (difficult) till the next variant appears (in my opinion, just a matter of weeks) or take Ivermectin orHCQ as soon as symptoms manifest (but not prophylactically).
Geert Vanden Bossche received his DVM from the University of Ghent, Belgium, and his PhD degree in Virology from the University of Hohenheim, Germany. He held adjunct faculty appointments at universities in Belgium and Germany. After his career in Academia, Geert joined several vaccine companies (GSK Biologicals, Novartis Vaccines, Solvay Biologicals) to serve various roles in vaccine R&D as well as in late vaccine development.
Geert then moved on to join the Bill & Melinda Gates Foundation’s Global Health Discovery team in Seattle (USA) as Senior Program Officer; he then worked with the Global Alliance for Vaccines and Immunization (GAVI) in Geneva as Senior Ebola Program Manager. At GAVI he tracked efforts to develop an Ebola vaccine. He also represented GAVI in fora with other partners, including WHO, to review progress on the fight against Ebola and to build plans for global pandemic preparedness.
Back in 2015, Geert scrutinized and questioned the safety of the Ebola vaccine that was used in ring vaccination trials conducted by WHO in Guinea. His critical scientific analysis and report on the data published by WHO in the Lancet in 2015 was sent to all international health and regulatory authorities involved in the Ebola vaccination program. After working for GAVI, Geert joined the German Center for Infection Research in Cologne as Head of the Vaccine Development Office. He is at present primarily serving as a Biotech / Vaccine consultant while also conducting his own research on Natural Killer cell-based vaccines.